Genmab (GMAB) reported Q1 DARZALEX net sales Tuesday of about $4 million, including $2.2 million in the US and $1.8 million in the rest of the world.
The company said it receives royalties on the worldwide net sales of DARZALEX from Johnson & Johnson (JNJ).
Genmab's shares were up 2% during Tuesday premarket activity.